/
CTKB
$4.34-$0.14 (-3.13%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$578.6M
129M shares
52-week range
$3.09 – $6.18
40% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-14.42
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $57.9M | $92.8M | $128.0M | $164.0M | $193.0M | $200.5M | $201.5M |
| Cost of revenue | $29.2M | $41.1M | $48.8M | $63.1M | $83.6M | $89.3M | $97.0M |
| Gross profit | $28.7M | $51.7M | $79.1M | $101.0M | $109.4M | $111.1M | $104.5M |
| Gross margin | 49.5% | 55.7% | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% |
| R&D | $8.9M | $13.7M | $24.4M | $34.9M | $44.2M | $39.4M | $36.5M |
| Operating income | −$17.3M | $13.7M | $9.2M | −$1.8M | −$27.8M | −$20.5M | −$40.4M |
| EBITDA | −$16.0M | $15.4M | $8.9M | $9.5M | −$4.4M | $4.8M | −$17.4M |
| Net income | −$16.8M | $19.4M | $3.0M | $2.6M | −$12.1M | −$6.0M | −$66.5M |
| Net margin | -29.1% | 20.9% | 2.3% | 1.6% | -6.3% | -3.0% | -33.0% |
| EPS (diluted) | -0.13 | 0.02 | 0.03 | 0.02 | -0.09 | -0.05 | -0.52 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $209M | $-0.35 | $-0.35–$-0.35 | 1 |
| 2027 | $223M | $-0.27 | $-0.27–$-0.26 | 1 |
| 2028 | $246M | $-0.23 | $-0.28–$-0.18 | 2 |
| 2029 | $259M | $-0.08 | $-0.08–$-0.08 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.09
Price
$4.34
Implied downside
-75%
Peer comparison
Cytek Biosciences, Inc. Common Stock
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
www.cytekbio.com- Employees
- 702
- IPO / List date
- Jul 23, 2021
- HQ
- FREMONT, CA
Held by traders on TradeandTell
No one on the platform currently holds CTKB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 676,700 | $3.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CTKB yet.
